Ascentage Pharma receives $100m payment from Takeda under exclusive option agreement
Ascentage Pharma, a leading global biopharmaceutical company specializing in novel therapies for cancer and other serious diseases, has announced the receipt of a US$100 million ... Read More
Takeda announces positive results for mezagitamab in Phase 2 ITP study
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab ... Read More
Takeda’s TAKHZYRO approved by EC for pediatric hereditary angioedema
Takeda has announced a significant advancement in the treatment of Hereditary Angioedema (HAE), with the European Commission's approval of TAKHZYRO (lanadelumab) for routine prevention in ... Read More
Takeda gets ADZYNMA FDA approval for cTTP treatment: A new era in rare disease therapy
Takeda has achieved a monumental milestone in rare disease therapy with the U.S. Food and Drug Administration's approval of ADZYNMA (ADAMTS13, recombinant-krhn) for the treatment ... Read More
Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis
Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its ... Read More
Takeda halts TAK-994 narcolepsy treatment development due to hepatotoxicity concerns
Takeda's pioneering Phase 2 trial of TAK-994, a potential treatment for narcolepsy type 1 (NT1), came to an abrupt halt due to hepatotoxicity concerns, according ... Read More
Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic ... Read More
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More